5 Key Takeaways

• 1

  A multimodal imaging study revealed significant heterogeneity in PARP inhibitor distribution across ovarian tumors.

• 2

  Lysosomes can act as reservoirs for PARP inhibitors, creating regions of high drug accumulation within tumors.

• 3

  Mass spectrometry imaging was used to visualize drug uptake in patient tumor tissue, highlighting intratumoral variability.

• 4

  High-drug regions showed enrichment for apoptotic and DNA damage response signatures, indicating potential therapeutic implications.

• 5

  Further studies are needed to explore how tumor architecture and lysosomal storage contribute to clinical resistance.